RxDoctor Payments Data

Kelly Chisholm

Family · Lambertville, MINPI 1366870974

Payments from drug & device makers

$8,997in general payments, 2019–2025

Across 358 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$1K
  • AstraZeneca$1K
  • Novo Nordisk$983
  • AbbVie$741
  • GSK$480
  • Lilly USA, LLC$479
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,997 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$54,385
Medicare patients
216
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin102$111,573
OzempicSemaglutide81$102,657
MounjaroTirzepatide29$57,431
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$56,742
XareltoRivaroxaban50$48,501
FarxigaDapagliflozin Propanediol41$44,554
JanuviaSitagliptin Phosphate36$43,563
TrulicityDulaglutide40$39,760
VraylarCariprazine Hcl17$29,292
EliquisApixaban35$26,530
RybelsusSemaglutide18$25,868
Nurtec OdtRimegepant Sulfate15$21,496
Xigduo XrDapaglifloz Propaned/Metformin20$20,056
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$18,093
TrintellixVortioxetine Hydrobromide19$15,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$983$128,52599 claims
Boehringer IngelheimJardiance$178$111,573102 claims
Lilly USA, LLCMounjaro, Trulicity$479$97,19169 claims
GSKTrelegy Ellipta, Anoro Ellipta$480$74,835101 claims
AstraZenecaFarxiga, Symbicort$1,044$52,15555 claims
Johnson & JohnsonXarelto$95$48,50150 claims
PfizerEliquis, Nurtec Odt$204$48,02550 claims
AbbVieVraylar, Linzess, Synthroid$741$47,45196 claims
MerckJanuvia$122$43,56336 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$173$15,66019 claims
NovartisEntresto$15$12,55113 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$103$12,27515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Lambertville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →